Litigation Intel
Tepezza Hearing Loss
Patients treated with Tepezza for thyroid eye disease report permanent hearing loss and tinnitus.
Tepezza litigation continues through federal discovery backed by documented FDA label changes, while plaintiff firms sustain active intake campaigns.
Score breakdown
Four dimensions, each 0-100, generated by AI from the recent signal feed plus general knowledge of the tort.
MDL proceedings in Illinois continue with steady case additions and ongoing discovery management, maintaining solid judicial activity.
Published clinical studies and the 2023 FDA label update regarding severe hearing impairment provide substantial scientific support for causation claims.
Plaintiff law firms maintain consistent digital and television advertising targeting patients treated with teprotumumab who developed hearing complications.
The litigation sits in mid-stage federal MDL proceedings, progressing through general discovery and bellwether trial preparation.
Scores are generated by AI from public sources for market research. They are not legal advice or a prediction of any outcome.
Buying cases in this litigation?
We can launch an exclusive campaign to your intake criteria within one week.
Signal feed
1 recent signals across news, FDA, PubMed, and court sources.
- 🧪 pubmed·PubMed·Hearing loss in hyperthyroid patients treated with teprotumumab (Tepezza(R)).
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery